Drug intelligence / Profile preview

paracetamol + chlorphenamine + phenylephrine

Development stage: Unknown
Lead developer: Carnot Laboratorios
Modality: Small Molecules
Administration: Oral

Overview

Rinofren is an over-the-counter (OTC) multi-symptom cold and flu medication developed and marketed by Carnot Laboratorios. It is a combination product containing paracetamol (an analgesic and antipyretic), chlorphenamine maleate (a first-generation antihistamine), and phenylephrine hydrochloride (a sympathomimetic decongestant). It is indicated for the symptomatic relief of the common cold and influenza, addressing symptoms such as fever, body aches, nasal congestion, and sneezing. The product is primarily available in Mexico and other Latin American markets as an "antigripal" treatment.

Brand names: Rinofren
Other names: Rinofren

Targets

COXADRA1A (α1A)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on paracetamol + chlorphenamine + phenylephrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paracetamol + chlorphenamine + phenylephrine.

Explore the full profile